A model and risk score for predicting nevirapine-associated rash among HIV-infected patients: In settings of low CD4 cell counts and resource limitation

Open AIDS Journal

Volumn 3, Issue , 2009, Pages 24-30

  Kiertiburanakul, Sasisopin ^a   Sungkanuparph, Somnuek ^a   Malathum, Kumthorn ^a   Watcharananan, Siriorn ^a   Sathapatayavongs, Boonmee ^a   Charoenyingwattana, Angkana ^a   Mahasirimongkol, Surakameth ^b   Chantratita, Wasun ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

^b MINISTRY OF PUBLIC HEALTH   (Thailand)

Author keywords

HIV; Model; Nevirapine; Prediction; Rash; Risk factor

Indexed keywords

LAMIVUDINE; NEVIRAPINE; STAVUDINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CD4 LYMPHOCYTE COUNT; DRUG DOSE ESCALATION; DRUG HYPERSENSITIVITY; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RASH; RECEIVER OPERATING CHARACTERISTIC;

EID: 77953455008     PISSN: None     EISSN: 18746136     Source Type: Journal    
DOI: 10.2174/1874613600903010024     Document Type: Article

References (40)

1. Guidelines for the use of antiretroviral agents in HIV-1-Infected adults and adolescents. U. S. Department of Health and Human Services (DHHS). November 3, 2008. http://aidsinfo.nih.gov/ contentfiles/AdultandAdolescentGL.pdf (accessed December 1, 2008).
2. D'Aquila RT, Hughes MD, Johnson VA, et al. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, doubleblind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. Ann Intern Med 1996, 124: 1019-1030
3. Viramune package insert. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc, January 2004.
4. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000, 356: 1423-1430
5. Pollard RB, Robinson P, Dransfield K. Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. Clin Ther 1998, 20: 1071-1092 (Pubitemid 29058411)
6. Montessori V, Press N, Harris M, Akagi L, Montaner JS. Adverse effects of antiretroviral therapy for HIV infection. CMAJ 2004, 170: 229-238 (Pubitemid 38134804)
7. Carr A, Vella S, de Jong MD, et al. A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIVinfected patients. The Dutch-Italian-Australian Nevirapine Study Group. AIDS 1996, 10: 635-641 (Pubitemid 26162992)
8. Kiertiburanakul S, Khongnorasat S, Rattanasiri S, Sungkanuparph S. Efficacy of a generic fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) in Thai HIV-infected patients. J Med Assoc Thai 2007, 90: 237-243 (Pubitemid 46377158)
9. Metry DW, Lahart CJ, Farmer KL, Hebert AA. Stevens-Johnson syndrome caused by the antiretroviral drug nevirapine. J Am Acad Dermatol 2001, 44 (Suppl 3): 354-357 (Pubitemid 32167665)
10. Namayanja GK, Nankya JM, Byamugisha JK, et al. Stevens - Johnson syndrome due to nevirapine. Afr Health Sci 2005, 5: 338-340
11. Ananworanich J, Moor Z, Siangphoe U, et al. Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs. AIDS 2005, 19: 185-192 (Pubitemid 40409537)
12. van Leth F, Andrews S, Grinsztejn B, et al. The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART. AIDS 2005, 19: 463-471
13. Antinori A, Baldini F, Girardi E, et al. Female sex and the use of anti-allergic agents increase the risk of developing cutaneous rash associated with nevirapine therapy. AIDS 2001; 15: 1579-1581 (Pubitemid 32744607)
14. Kondo W, Carraro EA, Prandel E, et al. Nevirapine-induced side effects in pregnant women: experience of a Brazilian university hospital. Braz J Infect Dis 2007; 11: 544-548
15. Kiertiburanakul S, Sungkanuparph S, Charoenyingwattana A, Mahasirimongkol S, Sura T, Chantratita W. Risk factors for nevirapine-associated rash among HIV-infected patients with low CD4 cell counts in resource-limited settings. Curr HIV Res 2008; 6: 65-69
16. Manosuthi W, Sungkanuparph S, Tansuphaswadikul S, et al. Incidence and risk factors of nevirapine-associated skin rashes among HIV-infected patients with CD4 cell counts <250 cells/microL. Int J STD AIDS 2007; 18: 782-786 (Pubitemid 351738885)
17. de Maat MM, ter Heine R, Mulder JW, et al. Incidence and risk factors for nevirapine-associated rash. Eur J Clin Pharmacol 2003; 59: 457-462
18. Martin AM, Nolan D, James I, et al. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts. AIDS 2005, 19: 97-99 (Pubitemid 40111026)
19. Vitezica ZG, Milpied B, Lonjou C, et al. HLA-DRB1*01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz. AIDS 2008, 22: 540-541 (Pubitemid 351317299)
20. Barreiro P, Soriano V, Casas E, et al. Prevention of nevirapineassociated exanthema using slow dose escalation and/or corticosteroids. AIDS 2000, 14: 2153-2157 (Pubitemid 30792489)
21. Anton P, Soriano V, Jimenez-Nacher I, et al. Incidence of rash and discontinuation of nevirapine using two different escalating initial doses. AIDS 1999, 13: 524-525
22. Zhou J, Phanupak P, Kiertiburanakul S, Ditangco R, Kamarulzaman A, Pujary S. TREAT Asia HIV Observational Database: Highly active antiretroviral treatment containing efavirenz or nevirapine and related toxicity in the TREAT Asia HIV Observational Database. J Acquir Immune Defic Syndr 2006, 43: 501-503 (Pubitemid 44737112)
23. Knobel H, Miro JM, Domingo P, et al. Failure of a short-term prednisone regimen to prevent nevirapine-associated rash: a double-blind placebo-controlled trial: the GESIDA 09/99 study. J Acquir Immune Defic Syndr 2001, 28: 14-18 (Pubitemid 33104522)
24. Knobel H, Miro JM, Mahillo B, et al. Failure of cetirizine to prevent nevirapine-associated rash: a double-blind placebocontrolled trial for the GESIDA 26/01 Study. J Acquir Immune Defic Syndr 2004, 37: 1276-1281 (Pubitemid 39281509)
25. Clark R. Sex differences in antiretroviral therapy-associated intolerance and adverse events. Drug Saf 2005, 28: 1075-1083 (Pubitemid 41775999)
26. Montaner JS, Cahn P, Zala C, et al. Randomized, controlled study of the effects of a short course of prednisone on the incidence of rash associated with nevirapine in patients infected with HIV-1. J Acquir Immune Defic Syndr 2003 33: 41-46 (Pubitemid 36547240)
27. Bersoff-Matcha SJ, Miller WC, Aberg JA, et al. Sex differences in nevirapine rash. Clin Infect Dis 2001, 32: 124-129
28. Hosmer DW, Lemeshow S. Applied logistic regression. 2nd ed. New York: John Wiley & Sons Inc 2000.
29. Moons KG, Harrell FE, Steyerberg EW. Should scoring rules be based on odds ratios or regression coefficients? J Clin Epidemiol 2002, 55: 1054-1055
30. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982, 143: 29-36.
31. Rosenberg AL. Recent innovations in intensive care unit riskprediction models. Curr Opin Crit Care 2002, 8: 321-330
32. Division of AIDS table for grading the severity of adult and pediatric adverse events. Public date: December, 2004. Available from URL http://www3.niaid.nih.gov/research/resources/DAIDSC linRsrch/PDF/Safety/ DAIDSAEGradingTable.pdf.
33. Winston A, Pozniak A, Smith N, et al. Dose escalation or immediate full dose when switching from efavirenz to nevirapinebased highly active antiretroviral therapy in HIV-1-infected individuals? AIDS 2004, 18: 572-574
34. Tansuphaswadikul S, Aung SE, Phonrat B, Kaewkungwal J, Pitisuttithum P, Maek-a-nantawat W. Predisposing factors for nevirapine toxicity among AIDS patients with low baseline CD4 count. Asian Pac J Allergy Immunol 2007, 25: 147-154 (Pubitemid 350081445)
35. Manosuthi W, Athichathanabadi C, Uttayamakul S, Phoorisri T, Sungkanuparph S. Plasma nevirapine levels, adverse events and efficacy of antiretroviral therapy among HIV-infected patients concurrently receiving nevirapine-based antiretroviral therapy and fluconazole. BMC Infect Dis 2007, 7: 14. (Pubitemid 46455921)
36. Manosuthi W, Kiertiburanakul S, Chaovavanich A, Sungkanuparph S. Plasma nevirapine levels and 24-week efficacy of a fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) among Thai HIV-infected patients. J Med Assoc Thai 2007, 90: 244-250 (Pubitemid 46377159)
37. Fischl MA. Antiretroviral therapy in 1999 for antiretroviral-naive individuals with HIV infection. AIDS 1999, 13: S49-59.
38. Schumacher M, Holländer N, Sauerbrei W. Resampling and crossvalidation techniques: a tool to reduce bias caused by model building? Stat Med 1997,16: 2813-2827
39. Kiertiburanakul S, Malathum K, Watcharananan S, Sathapatayavongs B, Sungkanuparph S. Predicting factors for unsuccessful switching from nevirapine to efavirenz in HIV-infected patients who developed nevirapine-associated skin rash. Int J STD AIDS 2009, 20: 176-179
40. Chantarangsu S, Mushiroda T, Mahasirimongkol S, et al. HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in Thai HIV-infected patients. Pharmacogenet Genomics 2009, 19: 139-146